New Intermediate Nail and RC Lag Screw Expand Gamma4 Portfolio to Meet the Needs of Surgeons and Their Patients
January 17 2024 - 7:00AM
Business Wire
Stryker’s Gamma4 Hip Fracture Nailing System Used in Over 19,000
Cases Since Launch
Stryker (NYSE: SYK), one of the world’s leading medical
technologies companies, has expanded its Gamma4 Hip Fracture
Nailing System, with the addition of an intermediate nail, the RC
Lag Screw, and an anti-rotation clip with sleeve components. Since
its launch in August of 2022, the Gamma4 System has been used in
over 19,000 cases across more than 850 facilities, solidifying its
position as a leading choice in orthopaedic procedures.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240117805597/en/
Stryker's Gamma4 System is indicated for
the treatment of stable and unstable fractures, as well as for
stabilization of bones and correction of bone deformities in the
intracapsular, trochanteric, subtrochanteric and shaft regions of
the femur (including osteoporotic and osteopenic bone). (Photo:
Business Wire)
"The Gamma4 System, with its rich 30-year legacy of innovation
and clinical history, has ushered in a new era of intramedullary
nailing systems for hip fractures,” said Eric Tamweber, Vice
President and General Manager, Stryker’s Trauma business. “Stryker
remains unwavering in our commitment to providing cutting-edge
orthopaedic solutions to meet the needs of our customers. While
Gamma4 has already made a significant impact, the new line
extension expands our nailing portfolio and provides surgeons with
options that are designed to streamline operative flow and improve
procedural efficiency.”
The Gamma4 System, which launched in 2022, is indicated for the
treatment of stable and unstable fractures, as well as for
stabilization of bones and correction of bone deformities in the
intracapsular, trochanteric, subtrochanteric and shaft regions of
the femur (including osteoporotic and osteopenic bone). The recent
line extension, including the Gamma4 intermediate nail and RC Lag
Screw, received 510(k) clearance in June 2023. Key features
include:
- Increased cutout resistance: The Gamma4 RC Lag Screw increases
cutout resistance by 15% compared to the standard Gamma4 lag
screw.1,2
- Increased fixation: The RC lag screw blades allow for 2mm of
additional surface area contact within the femoral head compared to
the standard Gamma4 lag screw.3
- New intermediate nail option: Designed to provide more isthmus
support than a trochanteric nail and faster procedural time
compared to a long nail.3,4
- Controlling intraoperative rotation: The anti-rotation clip and
sleeve components provide intraoperative stability in rotationally
unstable femoral head neck fragments.
“The Gamma4 Phase 2 launch of the intermediate nail, RC lag
screw, and anti-rotation clip is sure to provide additional support
to surgeons for treatment of challenging hip fractures,” said Dr.
Sanjit Konda, Director of Trauma at NYU Langone Orthopedics and
Jamaica Hospital Medical Center, and Chairman of Orthopedic Surgery
at MediSys Health Network. “Intertrochanteric hip fractures with
subtrochanteric extension can now be treated with a distally
targeted intermediate nail. Hip fractures with involvement of the
basicervical neck region can be provisionally stabilized with the
anti-rotation clip and sleeve during lag screw insertion. The Phase
2 launch of these additional Gamma4 features will expand the
surgeon's toolbox and add to an already best-of-class nailing
system.”
About Stryker
Stryker is a global leader in medical technologies and, together
with its customers, is driven to make healthcare better. The
company offers innovative products and services in MedSurg,
Neurotechnology, Orthopaedics and Spine that help improve patient
and healthcare outcomes. Alongside its customers around the world,
Stryker impacts more than 130 million patients annually. More
information is available at www.stryker.com.
Dr. Sanjit Konda is a paid consultant of Stryker Trauma and
Extremities. The opinions expressed by Dr. Sanjit Konda are those
of Dr. Sanjit Konda and not necessarily those of Stryker.
Individual experiences may vary.
A surgeon must always rely on his or her own professional
clinical judgment when deciding whether to use a particular product
when treating a particular patient. Stryker does not dispense
medical advice and recommends that surgeons be trained in the use
of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth
of Stryker’s product offerings. A surgeon must always refer to the
package insert, product label and/or instructions for use before
using any of Stryker’s products. Products may not be available in
all markets because product availability is subject to the
regulatory and/or medical practices in individual markets. Please
contact your sales representative if you have questions about the
availability of products in your area.
G4-FL-2, 11-2023
References
- Internal Report № D0000093463, Rev AC, Sch�nkirchen,
Germany
- Internal Report № D0000245312, Rev AE, Sch�nkirchen,
Germany
- G4-ST-1, Rev-3, 07-2023
- Internal Report № D0000250608. Rev AA, Sch�nkirchen,
Germany
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117805597/en/
Andrea Sampson President/CEO, Sampson Public Relations Group
asampson@sampsonprgroup.com 562.304.0301
Stryker (NYSE:SYK)
Historical Stock Chart
From Apr 2024 to May 2024
Stryker (NYSE:SYK)
Historical Stock Chart
From May 2023 to May 2024